Form 4: PLUS THERAPEUTICS CEO's Future Stock Vesting Detailed

PLUS THERAPEUTICS CEO Marc H. Hedrick reported future vesting of Restricted Stock Units, impacting his beneficial ownership of common stock.

Summary

• Marc H. Hedrick, CEO and Director of PLUS THERAPEUTICS, INC. (PSTV), reported future changes in his beneficial ownership of common stock due to the vesting of Restricted Stock Units (RSUs).
• On April 1, 2026, 159,681 shares of common stock are expected to be acquired through the vesting of an RSU grant, which vests in twelve substantially equal quarterly installments beginning October 1, 2025. Following this specific acquisition, Hedrick's direct beneficial ownership of common stock is reported as 499,468 shares.
• Also on April 1, 2026, 201,632 shares of common stock are expected to be disposed of, likely related to the vesting of another RSU grant. This RSU grant vests in twelve substantially equal quarterly installments beginning April 1, 2026. Following this specific disposition, Hedrick's direct beneficial ownership of common stock is reported as 701,100 shares.
• Each RSU represents a contingent right to receive one share of the issuer's Common Stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, representing routine insider compensation through RSU vesting as per pre-existing agreements, with no immediate positive or negative implications for company fundamentals.

Positives

• The vesting of Restricted Stock Units indicates the CEO's continued long-term incentive compensation structure is in effect, aligning management interests with shareholder value over time.

Negatives

• The disposition of 201,632 shares of common stock on April 1, 2026, likely related to tax obligations or a pre-planned sale upon RSU vesting, represents a reduction in the CEO's direct holdings from that specific transaction.

Future Outlook

The filing details the future vesting schedule for the CEO's Restricted Stock Units, with installments beginning in October 2025 and April 2026, indicating a structured long-term compensation plan.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, reflecting routine compensation events such as RSU vesting. These transactions are common across industries for executive incentive plans.

Related Party Transactions

• The reported transactions are related to the compensation of Marc H. Hedrick, the Chief Executive Officer and a Director of PLUS THERAPEUTICS, INC., which is a standard form of related party compensation.

Stakeholder Impact

• Shareholders will experience a minor dilutive effect over time as shares are issued upon RSU vesting, which is a common aspect of equity-based compensation plans.

Next Steps

• Continued vesting of the CEO's Restricted Stock Units in twelve substantially equal quarterly installments, with the next vesting events scheduled to begin October 1, 2025, and April 1, 2026.

Key Dates

Recommendation

This Form 4 filing details routine insider compensation through RSU vesting and does not provide new material information that would alter the fundamental investment thesis for PLUS THERAPEUTICS, INC. Investors should hold their positions and consider broader company performance and market conditions.

Keywords

PLUS THERAPEUTICS, PSTV, Marc H. Hedrick, CEO, Insider Transaction, Form 4, Restricted Stock Units, RSU, Stock Vesting, Beneficial Ownership